Literature DB >> 10489921

Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C.

A Landau, L Castera, C Buffet, G Tertian, G Tchernia.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10489921     DOI: 10.1023/a:1026643500569

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  6 in total

1.  Hemolytic anemia secondary to interferon treatment for chronic B hepatitis.

Authors:  G Fornaciari; C Bassi; M Beltrami; E Castagnetti; S Maccari; A C Plancher
Journal:  J Clin Gastroenterol       Date:  1991-10       Impact factor: 3.062

2.  Alpha-interferon and immune hemolytic anemia.

Authors:  L P Akard; R Hoffman; L Elias; J H Saiers
Journal:  Ann Intern Med       Date:  1986-08       Impact factor: 25.391

3.  Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Authors:  K C Conlon; W J Urba; J W Smith; R G Steis; D L Longo; J W Clark
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

4.  Haemolytic anaemia to the alpha-interferon treatment: a proposed mechanism.

Authors:  L Barbolla; C Paniagua; J Outeiriño; E Prieto; J Sánchez Fayos
Journal:  Vox Sang       Date:  1993       Impact factor: 2.144

5.  A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

Authors:  G Fattovich; G Giustina; S Favarato; A Ruol
Journal:  J Hepatol       Date:  1996-01       Impact factor: 25.083

6.  Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia.

Authors:  A I Radin; P Buckley; T P Duffy
Journal:  Hematol Pathol       Date:  1991
  6 in total
  1 in total

1.  Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.

Authors:  Peter Rieckmann; Paul O'Connor; Gordon S Francis; Graham Wetherill; Enrica Alteri
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.